Adam Kalbermatten leads the BD Pharmaceutical Systems Advanced Drug Delivery Commercial Development Team. Adam is focused on partnering with pharmaceutical and biotechnology companies to provide drug delivery solutions and services that help commercialize drug device combination product therapies. Prior to joining BD, Adam served as Chief Executive Officer of ZebraSci, a combination product contract research and development organization (CRDO) acquired by BD in 2021. Prior to leading the ZebraSci organization, Adam held several leadership roles at Terumo, BD, and Merck. Adam holds a Bachelor of Engineering in Mechanical Engineering and a Master of Engineering in Engineering Management from Stevens Institute of Technology and an MBA from Columbia University.